Despite Hitting Mid-Stage Trial Endpoint Goal, Vertex Strikes Out Rare Lung Disease Candidate; Stock Tumbles
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced the Phase 2 data evaluating VX-864 in alpha-1 antitrypsin deficiency (AATD) with the PiZZ genotype.
